°ÅÀÖÊÓƵ

Memorial Sloan Kettering Cancer Center, The Rockefeller University and °ÅÀÖÊÓƵ announced on Oct. 31 that they have established a new drug discovery company called Bridge Medicines.

Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

"Bridge Medicines is a transformative concept for therapeutics development that will provide enormous hope to patients and incredibly exciting opportunities for researchers to take their discoveries into the clinic," said °ÅÀÖÊÓƵ Interim Dean Augustine M.K. Choi. "°ÅÀÖÊÓƵ is honored to be part of this groundbreaking investment in medicine."

.